A medical oncologist and internist at a Southwest Comprehensive Cancer Center discusses their use of MRD / ctDNA monitoring assays. They utilize these technologies most often in melanoma patients but expect there to be more uptake of these tests in other common cancers such as lung, CRC, breast, and prostate. A major hindrance to their recommendation of using these tests is around lack of clinical data and guideline inclusions, in which they imagine vendors who release reputable data the most quickly will see the most success in this market. They are most familiar with Guardant and Natera as vendors in this space and are decently satisfied with both providers. They mentioned time to market / both these companies being early movers were key to their success.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.